Pharmaceutical company Dr Reddy’s is developing new treatment options for Covid


Drugs major Dr Reddy’s Laboratories is working to develop new treatment options for COVID-19 patients that he aims to launch over the next few months while ensuring an uninterrupted supply of his existing line of infectious disease products on the market. market, according to a senior company official.

“We are motivated to serve patients in every way possible and with the utmost urgency. This is reflected in the multiple collaborations we have entered into to develop and commercialize a wide range of preventive and curative options for COVID treatment,” Dr Reddy’s Laboratories Co-Chairman & Managing Director GV Prasad said on call to analyst, as reported by the news agency PTI.

In recent weeks, the pharmaceutical company has increased the supply of several drugs, including Remdesivir, to meet increased demand, he added.

“We are also working on the launch of new treatment options, which we will bring to market in the coming months. We have also ensured that the supply of our existing drugs continues uninterrupted and we continue to meet market demand for all of our markets. “, noted Prasad.

Commenting on the business opportunities arising from Sputnik V, Erez Israel, CEO of Dr Reddy’s, said: “We have the rights for the first 250 million doses for India, which translates to 125 million patients. get out of Russia. “

And in the meantime, the company has partnered with six subcontractors (manufacturing partners) to produce the product locally in India, he noted.

“In addition, there are discussions with RDIF for Sputnik light as well as additional commitment for India’s future. And we are also in discussion with them on quantities and rights, asset permits. for other countries, so this is the overall vision that we have at this stage of Sputnik, ”noted Israeli.

When asked when the drug major would be able to deliver the 250 million doses to the country, he said: “I anticipate that by July, maybe August, the main supply will come from the Russia.”

Regarding the start of production and local supplies of the COVID-19 vaccine, he noted: “The first quantities will come from Indian manufacturers, hopefully by August and September. This of course depends on the qualifications of those sites and the ability to respond to bridging studies etc, but at least that’s anticipation. If this plan is in place, we can process these quantities within 12 months.

Currently, the company is working on its distribution network, said Israeli. He noted that the intention is for India to be a big hub for Sputnik V. “And so, part of that amount when filled, what is needed for India will also be for export. But it is not concluded at this stage, it is under discussion, ”said Israeli.

(With PTI entries)

To subscribe to Mint newsletters

* Enter a valid email address

* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint. Download our app now !!

Source link

Leave A Reply

Your email address will not be published.